S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Bill Gates is raving about WHAT?! (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
New trade alert coming … (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Bill Gates is raving about WHAT?! (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
New trade alert coming … (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Bill Gates is raving about WHAT?! (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
New trade alert coming … (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Tech Genius Reveals #1AI Stock For 2024 (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Bill Gates is raving about WHAT?! (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
New trade alert coming … (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

$10.03
+0.73 (+7.85%)
(As of 03/1/2024 ET)
Today's Range
$9.30
$10.61
50-Day Range
$6.85
$11.96
52-Week Range
$5.22
$19.00
Volume
43,856 shs
Average Volume
7,365 shs
Market Capitalization
$29.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.00

Oncternal Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
587.9% Upside
$69.00 Price Target
Short Interest
Healthy
0.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Oncternal Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$6,455 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($13.40) to ($11.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

377th out of 950 stocks

Pharmaceutical Preparations Industry

178th out of 440 stocks


ONCT stock logo

About Oncternal Therapeutics Stock (NASDAQ:ONCT)

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

ONCT Stock Price History

ONCT Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Oncternal Therapeutics Inc ONCT
ONCT Jul 2024 7.500 call
ONCT Apr 2024 2.500 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Oncternal Therapeutics Announces Reverse Stock Split
Oncternal Therapeutics upgraded to Buy from Hold at Brookline
Q3 2023 Oncternal Therapeutics Inc Earnings Call
Earnings Outlook For Oncternal Therapeutics
See More Headlines
Receive ONCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/03/2024
Next Earnings (Confirmed)
3/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCT
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$69.00
High Stock Price Target
$180.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+587.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-44,170,000.00
Net Margins
-6,330.05%
Pretax Margin
-6,330.04%

Debt

Sales & Book Value

Annual Sales
$1.49 million
Book Value
$21.64 per share

Miscellaneous

Free Float
2,712,000
Market Cap
$29.59 million
Optionable
Optionable
Beta
1.27
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report














ONCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncternal Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ONCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCT, but not buy additional shares or sell existing shares.
View ONCT analyst ratings
or view top-rated stocks.

What is Oncternal Therapeutics' stock price target for 2024?

6 analysts have issued twelve-month target prices for Oncternal Therapeutics' shares. Their ONCT share price targets range from $26.00 to $180.00. On average, they predict the company's stock price to reach $69.00 in the next twelve months. This suggests a possible upside of 587.9% from the stock's current price.
View analysts price targets for ONCT
or view top-rated stocks among Wall Street analysts.

How have ONCT shares performed in 2024?

Oncternal Therapeutics' stock was trading at $10.7240 at the beginning of 2024. Since then, ONCT shares have decreased by 6.5% and is now trading at $10.03.
View the best growth stocks for 2024 here
.

When is Oncternal Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our ONCT earnings forecast
.

How can I listen to Oncternal Therapeutics' earnings call?

Oncternal Therapeutics will be holding an earnings conference call on Thursday, March 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Oncternal Therapeutics' earnings last quarter?

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) released its quarterly earnings data on Thursday, November, 4th. The company reported ($3.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.20) by $0.60. The company earned $2.13 million during the quarter, compared to analysts' expectations of $1.30 million. Oncternal Therapeutics had a negative trailing twelve-month return on equity of 85.29% and a negative net margin of 6,330.05%. During the same quarter in the prior year, the business earned ($4.40) EPS.

When did Oncternal Therapeutics' stock split?

Shares of Oncternal Therapeutics reverse split on Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Oncternal Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX).

Who are Oncternal Therapeutics' major shareholders?

Oncternal Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pasadena Private Wealth LLC (16.96%), Citadel Advisors LLC (1.84%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Chase C Leavitt, Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent and Salim Yazji.
View institutional ownership trends
.

How do I buy shares of Oncternal Therapeutics?

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONCT) was last updated on 3/3/2024 by MarketBeat.com Staff